US OptionsDetailed Quotes

VSTM241115C3000

Watchlist

0.40
-0.10-20.00%

15min DelayClose Oct 25 15:58 ET

0.43High0.40Low

Verastem Stock Discussion

Jaguar8

Oct 18 23:13

Webcast today. Possible PR Monday.

$Verastem (VSTM.US)$ Verastem Oncology Presents Updated Data On Avutometinib And Defactinib Combo In Recurrent Low-Grade Serous Ovarian Cancer At IGCS 2024
Robust overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumabPatients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months)...

NEWS

$Verastem (VSTM.US)$
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
Verastem Oncology presented updated data from the Phase 2 RAMP 201 trial evaluating avutometinib and defactinibcombination in recurrent low-grade serous ovarian cancer (LGSOC) at the IGCS 2024 Annual Meeting. Key findings include:
- 31% overall response ...

Trytosaveabit

Oct 9 05:19

Watching for something good to maybe come out of this? October 16th to 18th!

$Verastem (VSTM.US)$ Verastem Oncology Announces Details for the Oral Presentation of the Mature Ramp 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the Igcs 2024 Annual Meeting

Teddy123

Oct 9 05:14

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual M

$Verastem (VSTM.US)$
BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/G...

Trytosaveabit

Sep 10 15:29

Looking for something good outa dis!

$Verastem (VSTM.US)$ Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18 at 3:40 pm EDT.

Jaguar8

Sep 10 07:08

NEWS

$Verastem (VSTM.US)$
Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting
Verastem Oncology (VSTM) announced the acceptance of a late-breaking abstract for oral presentation at the International Gynecologic Cancer Society (IGCS) Annual Meeting in October 2024. The presentation will feature mature data from the Phase 2 RAMP 201 clinical trial, evaluating the combination of avutometinib (RAF/MEK ...

No comment yet